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Abstract
Candida is an important cause of bloodstream infections (BSI), causing significant mortality and morbidity in health care
settings. From January 2008 to December 2010 all consecutive patients who developed candidemia at San Martino University
Hospital, Italy were enrolled in the study. A total of 348 episodes of candidaemia were identified during the study period
(January 2008–December 2010), with an incidence of 1,73 episodes/1000 admissions. Globally, albicans and non-albicans
species caused around 50% of the cases each. Non-albicans included Candida parapsilosis (28.4%), Candida glabrata (9.5%),
Candida tropicalis (6.6%), and Candida krusei (2.6%). Out of 324 evaluable patients, 141 (43.5%) died within 30 days from the
onset of candidemia. C. parapsilosis candidemia was associated with the lowest mortality rate (36.2%). In contrast, patients
with C. krusei BSI had the highest mortality rate (55.5%) in this cohort. Regarding the crude mortality in the different units,
patients in Internal Medicine wards had the highest mortality rate (54.1%), followed by patients in ICU and Hemato-Oncology
wards (47.6%). This report shows that candidemia is a significant source of morbidity in Italy, with a substantial burden of
disease, mortality, and likely high associated costs. Although our high rates of candidemia may be related to high rates of BSI in
general in Italian public hospitals, reasons for these high rates are not clear and warrant further study. Determining factors
associated with these high rates may lead to identifying measures that can help to prevent disease.
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Introduction
Candida is an important cause of bloodstream infections (BSI),
causing significant mortality and morbidity in health care settings.
The incidence of candidemia is growing with the increasing
complexity of surgical procedures, the existence of patient popula-
tions at higher risk of infection, and the changes in patient
demographic characteristics. Its overall incidence raised fivefold in
the past ten years and Candida spp. is currently between the fourth and
the sixth most common nosocomial bloodstream isolate in American
and European studies [1,2]. However, candidemia rates vary
geographically. For example, an increasing incidence of candidemia
in Iceland was reported for the period between 1980 and 1999 [3],
but the same was not observed in Switzerland, where a national
surveillance study showed that the incidence of candidemia had
remained unchanged during the period of 1991 to 2000 [2]. It
therefore seems that differences do exist in the epidemiology of
candidemia between different countries, underscoring the need for
continuous surveillance to monitor trends in incidence, species
distribution, and antifungal drug susceptibility profiles. The epide-
miology of candidemia has been studied extensively in the United
States, Europe, and some countries in South America.
Candidemia remains associated with high crude and attribut-
able mortality rates and with increased costs of care and duration
of hospitalization. Attributable mortality has been reported to
range from 5% to 71%, and crude mortality rates have been
reported to be as high as 81% [4,5]. In terms of species of Candida,
recently, a shift towards non-albicans species was reported by some
authors especially in haematological, transplanted and intensive
care unit (ICU) patients [6–8].
A reduced antifungal susceptibility in non-albicans species and a
correlation with routine fluconazole prophylactic use has been
suggested [7,9]. Intrinsic and emerging resistance to azoles actually
represents a major challenge for empirical therapeutic and
prophylactic strategies [10].
This study was performed to evaluate contemporary epidemi-
ology, species distribution, antifungal susceptibly and outcome of
candidema BSI in an Italian hospital.
Methods
All consecutive patients who developed candidemia at San
Martino University Hospital, Italy, a 1,500 beds tertiary care
hospital with about 70,000 admissions per year were enrolled in
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24198
Table 1. Patient characteristics and incidence (episode/1000 person/day).
Candida species
C. albicans C.parapsilosis C.glabrata C.tropicalis C. krusei Other All
(n = 170) (n =99) (n =33) (n =23) (n =9) (n=14) (n=348)
48,9% 28,4% 9,5% 6,6% 2,6% 4,0% 100,0%
Patients characteriristic
Mean age (standard deviation) 70,1 (615,72) 66,6 (616,03) 69,45 (613,4) 73,35 (615,32) 47,0 (615,73) 67,07 (620,72) 68,7 (±15,95)
Male sex, n (%) 99 (57,89) 49 (49,49) 18 (54,54) 13 (56,52) 6 (66,67) 8 (57,14) 185 (53,31)
Underline diseases, n (%)
- Surgery 75 (47,77) 54 (34,4) 13 (8,28) 9 (5,73) 2 (1,27) 4 (2,55) 157
- Solid organ transplantation 2 (40) 2 (40) 0 (0) 0 (0) 0 (0) 1 (20) 5
- Hematologic malignancy 11 (40,75) 7 (25,93) 1 (3,7) 1 (3,7) 6 (22,22) 1 (3,7) 27
- HIV 1 (33,33) 0 (0) 0 (0) 1 (33,33) 0 (0) 1 (33,33) 3
- Solid tumor 52 (52,53) 30 (30,3) 8 (8,08) 5 (5,05) 0 (0) 4 (4,04) 99
- Cardiovascular disease 73 (51) 40 (28) 10 (7) 10 (7) 2 (1,4) 8 (5,6) 143
- Diabetes mellitus 20 (51,28) 11 (28,20) 2 (5,13) 4 (10,26) 0 (0) 2 (5,13) 39
Incidence (episodes/1000
admissions)
2008 0,55 0,39 0,08 0,08 0,01 0,07 1,18
2009 0,95 0,48 0,11 0,1 0,06 0,07 1,77
2010 1,09 0,64 0,33 0,17 0,07 0,07 2,37
doi:10.1371/journal.pone.0024198.t001
Figure 1. Distribution of the Candida species according to underlying pathology/medical care (n).
doi:10.1371/journal.pone.0024198.g001
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the study during the period January 2008–December 2010.
Patients with at least one positive blood culture for Candida spp.
And a compatible clinical illness were identified through the
microbiological laboratory data base and all informations was
recorded in an electronic database. For each patient, only the first
episode of candidemia was recorded. Detailed information with
regard to candidemia episodes were analyzed, including underly-
ing patient characteristics, the specific fungal pathogen and
species, resistance to antifungals and survival. Patients whose
cultures grew .1 species of Candida were excluded from the
analysis. Patients with candidemia were followed prospectively for
30 days or until their discharge from the hospital. Outcome was
recorded only for patients with at least 30 days follow-up after the
initial episode of candidemia.
During the study period there were no changes in microbio-
logical laboratory techniques. Candida species were isolated from
blood using BACTEC 860 system (Becton Dickinson, INC,
Sparks, MD). The species were identified using API-32C system
(bioMerieux Vitek, Inc, St. Louis, MI). Antifungal susceptibility
testing of isolates of Candida spp. was performed by the reference
broth microdilution method described by the CLSI [11] . The
interpretive breakpoints used for tests were based on values
recommended by the CLSI and EUCAST [11,12].
The following antifungal drugs were tested: amphotericin B,
caspofungin, fluconazole, itraconazole and voriconazole.
The Chi-square-test or the Fisher Exact-test were used to
compare categorical variables.
The study was approved by the local institutional review board
(Comitato Etico, Azienda Ospedaliera Universitaria San Martino)
and written patient consent was not required because of the
observational nature of this study.
Results
A total of 348 episodes of candidaemia were identified during the
study period (January 2008–December 2010), with an incidence of
1,73 episodes/1000 admissions as shown in table 1. Incidence of
candidemia increased from 1,18 in 2008 to 2,37 episodes/1000
admission in 2010 (Table 1). The demographic and clinical
characteristics of the patients are summarized in table 1. The
majority of patients (93,1%) had one or more comorbidity at the time
of the diagnosis of candidaemia. One hundred fifty-seven patients
(45,1%) had urdergone a surgical intervention, 143 (41,1%) had solid
tumor, 39 (11,2%) were diabetic, 27 (7,7%) had hematologic
malignancies, 5 (1,4%) had received a solid organ transplantation
and 3 (0,9%) had human immunodeficiency virus infection.
Table 2. Antifungal susceptibility test results for selected species of Candida isolated during the study period.
Species (n) Antifungal agent
MIC range
(mg/ml)
MIC50
(mg/ml)
MIC90
(mg/ml) No. (%) of resistant or SDD isolates
CLSI EUCAST
C. albicans (167) Amfotericin B 0,016–1 0,5 0,5 na 0
Caspofungin 0,002–0,25 0,06 0,125 0 Na
Fluconazole 0,125–256 0,25 1 2 (1,3) 6 (3,6)
Itraconazole 0,006–256 0,125 0,25 18 (11,9) Na
Voriconazole 0,002–256 0,003 0,016 2 (1,3) 6 (3,6)
C. parapsilosis (98) Amfotericin B 0,008–1 0,5 0,5 na 0
Caspofungin 0,03–1 0,5 1 0 Na
Fluconazole 0,06–8 1 4 0 2(2)
Itraconazole 0,006–0,5 0,125 0,25 23 (26,4) Na
Voriconazole 0,006–0,125 0,016 0,06 0 0
C. glabrata (33) Amfotericin B 0,03–1 0,05 1 na 0
Caspofungin 0,006–0,25 0,06 0,125 0 Na
Fluconazole 0,5–256 16 32 27 (81,8) 31 (93,9)
Itraconazole 0,125–16 1 8 29 (96,6) Na
Voriconazole 0,006–8 0,25 1 3 (9,6) 16(48,5)
C. tropicalis (23) Amfotericin B 0,06–2 0,5 1 na 0
Caspofungin 0,016–0,16 0,03 0,125 0 Na
Fluconazole 0,25–256 1 8 3 (14,3) 6 (26)
Itraconazole 0,125–16 0,25 0,5 20 (95,2) Na
Voriconazole 0,006–16 0,06 0,5 2 (9,5) 7 (30,4)
All Candida spp. (342) Amphotericin B 0.008–1 0.5 0.5 na 0
Caspofungin 0.002–1 0.06 0.125 0 Na
Fluconazole 0.06–256 0.5 4 43 (12,6) 56 (16,4)
Itraconazole 0.006–256 0.125 0.5 106 (31) Na
Voriconazole 0.006–256 0.06 0.5 4 (1.2) 34 (9,9)
SDD: susceptible dose dependence; na: breakpoint not available.
CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing.
doi:10.1371/journal.pone.0024198.t002
Nosocomial Candidemia in Italy
PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24198
The distribution of isolated Candida species is shown in figure 1.
Globally, albicans and non-albicans species caused around 50% of
the cases each. Non-albicans included Candida parapsilosis (28.4%),
Candida glabrata (9.5%), Candida tropicalis (6.6%), and Candida krusei
(2.6%). The distribution of albicans and non-albicans strains
differed according to the type of patient population and risk
factors, as shown in Figure 1. In transplant patients, C. albicans was
isolated in 40% of the cases, Candida parapsilosis in 33% and Candida
glabrata in 18%; in Hemato-Oncology C. albicans accounted for
40% of the cases and C. parapsilosis and C. krusei for 20% each; on
the other hand in ICU C. albicans was isolated in 66% of the cases.
Table 2 shows the results of the in vitro activity of 5 systemically
active antifungal agents tested against 342 BSI isolates of Candida
spp. Based on CLSI and EUCAST breakpoints [11,12]. The rate
of susceptibility to fluconazole was 98.7% and 96,4% for C. albicans
and 100% and 98% for C. parapsilosis, according to CLSI and
EUCAST breakpoints, respectively. Decreased susceptibility to
fluconazole was mostly seen with C. glabrata [81.8% and 93,9%
susceptible in a dose-dependent manner (SDD) or resistant (R) for
CLSI and EUCAST, respectively] and C. tropicalis (14.3% and
26% SDD or R, for CLSI and EUCAST). Overall, 12.6% with
CLSI and 16,4% with EUCAST method of the 342 isolates tested
were either SDD or resistant to fluconazole. Caspofungin
demonstrated potent activity against C. albicans, C. glabrata and C.
tropicalis with higher MICs C. parapsilosis (MIC90 1 mg/mL).
Resistance to caspofungin was not found with CLSI method.
The rates of SDD or R to itraconazole is particularly high in
Candida spp. (31%).
Patient outcomes 30 days stratified by Candida species and type
of units are reported in table 3. Out of 324 evaluable patients, 141
(43.5%) died within 30 days from the onset of candidemia. C.
parapsilosis candidemia was associated with the lowest mortality
rate (36.2%).In contrast, patients with C. krusei BSI had the highest
mortality rate (55.5%) in this cohort. No statistically significant
differences were observed.
No statistically significant differences were observed with C.
tropicalis, C. krusei, or other Candida species.
Regarding the crude mortality in the different units, patients in
Internal Medicine wards had the highest mortality rate (54.1%),
followed by patients in ICU and Hemato-Oncology wards
(47.6%).
Discussion
Several studies have shown a substantial increase in the
incidence of candidemia in the past 2 decades. Our data show
that in our hospital the incidence of candidemia has increased
steadily and significantly in the past 3 years. Our rates are higher
than those reported for centers in the Northern Hemisphere,
including the United States (0.28 to 0.96 case per 1,000
admissions) [13,14], Canada (0.45 case per 1,000 admissions)
[15] and some European countries (0.20 to 1.09 case per 1,000
admissions) [16–18] and much higher than those reported in
Finland (0.026 to 0.03 case per 1,000 admission [19]. The
differences in candidemia rates between countries may reflect
differences in representativeness and age distributions of the study
populations, variations in health care practices, patterns using
blood cultures, and antibiotic usage as well as the resistance
situation.
Over the past 10 years, some studies have reported a shift in the
etiology of candidemia. While C. albicans is still considered the most
common species causing candidemia, increasing rates of candide-
mia caused by C. tropicalis, C. parapsilosis, C. glabrata, and C. krusei
have been reported worldwide [6–8,20]. The reasons for the
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emergence of non-C. albicans species are not completely under-
stood, but some medical conditions may consistently impact the
risk of developing candidemia due to non-C. albicans species: C.
parapsilosis fungemia has been associated with vascular catheters
and parenteral nutrition [21]. C. tropicalis candidemia is associated
with cancer and neutropenia [22], and C. krusei and C. glabrata
fungemias are associated with previous exposure to azoles [9,23].
The findings from our surveillance are partially supportive of these
reports. We observed a light predominance of non– C. albicans
Candida species (51.1%), however C. albicans was the most
frequently isolated species (48.9%). Our series clearly consolidates
the concept that candidemia due to C. krusei is rare in Italy and
shows that C. parapsilosis accounts for the large majority of non-C.
albicans species. Why C. krusei is unusual in Italy is not clear, but the
wide geographic variability in the species distribution suggests that
factors other than the use of fluconazole may be important,
including demographic characteristics and the use of antibiotics.
However, although the proportion of C. krusei infections in Italy is
small, the burden of this species is more or less similar to rates
reported recently in Spain [18].
We report a low rate of C. tropicalis candidemia similar to those
published in European and North American series (2 to 10% in
Europe and 10 to 12% in the United States and Canada) [24,25].
Traditionally, C.tropicalis has been the second and C.glabrata the
third or fourth most common Candida species recovered from
blood [6,7].
In our study C.parapsilosis surpassed the other non-albicans to
become the most common species isolated after C.albicans. The
high incidence of C.parapsilosis candidemia has been previously
reported in South American and Italian hospitals [26,27].
C. albicans dominated in our study only in ICU with 66% of the
species isolated and is probably related to the restricted
fluconazole prophylaxis initiated in 2005 as already published
[9]. Non-albicans Candida occurs frequently among haemato-
oncologial and in solid organ transplant patients, confirming
previous observations [28].
Interesting differences emerged in the profiles of patients with
candidal BSI between our data and those previously described.
Canadian figures [29] identified that 64% of episodes of
nosocomial fungaemia occurred in patients in ICU. In contrast,
only 19,4% of episodes in our study arose in ICU patients; this
proportion being only a small amount lower than that which arose
from patients in the surgical units (23%). In our study in contrast
with other experiences, an unusually large proportion (41%)
occurred among patients in a general internal medicine service.
We hypothesise that this variety of patterns reflects differences in
the organisation and resourcing of healthcare delivery in various
countries rather than significant differences in the characteristics of
the different populations studied.
Antifungal resistance was a rare finding in our study and was
restricted to azoles. As with a recently Spanish study [18], none of
our Candida bloodstream isolates had MICs of .2 mg/ml for
amphotericin B. Our proportion of fluconazole-resistant or SDD
isolates (12,6% with CLSI and 16,4% with EUCAST breakpoints)
was higher than the rates observed with European (6,3%) and
North American (6.6%) isolates [18,30]. Voriconazole was the
azole which exhibited the best in vitro antifungal activity. As
reported by others [31] caspofungin demonstrated excellent
activity. Important differences in susceptibility, especially for
azoles were observed when the CLSI and EUCAST reference
methods have been compared [11,12].
Retrospective cohort studies involving patients with candidemia
and varying underlying diseases have revealed worldwide crude
and attributable mortality rates of 30%–81% and 5%–71%,
respectively [24,32–34]. The severity of candidaemia is confirmed
by the high crude mortality rate found in the ECMM survey (38%)
[16] as well as in Finland (35%) [35] and in the Barcelona area
(44%) [17]. In our series, patients with candidemia had a crude 30
days mortality rate of 43.5%, similar to that reported in Spain.
Similar to other reports, patients with C. parapsilosis candidemia
had the lowest death rates [25,36] while Candida krusei, C. glabrata
and C. tropicalis BSIs appeared particularly severe, with an
unfavourable outcome in more than 40% of patients [5,16]. This
high crude mortality rate of BSIs caused by these species may be
due to their occurrence in patients with underlying life-threatening
conditions.
Mortality rate at 30 days was higher in Internal Medicine
Department (51,1%) and lower in surgical patients (29,3%). These
data are different with those reported in other similar studies were
the highest mortality has been found in ICU or tumour and
haematology patients [37,38]. Certainly the severity of the
underlying medical condition greatly influences the crude
mortality rate in these patient populations, however for the
patient in Internal Medicine inappropriate therapy could
represent an important variable – consisting mostly of omission
of initial empirical therapy and an inadequate choice of
antifungals – which has been associated with increased mortality
[39,40]. Some limitations of the study must be stressed. The major
one is that this is a single centre study and even if it comes from a
very large Italian hospital, regional conditions such as features of
the patient population and antimicrobial/infection control prac-
tices of this specific tertiary care centre may influence the results.
This report shows that candidemia is a significant source of
morbidity in Italy, with a substantial burden of disease, mortality,
and likely high associated costs. Although our high rates of
candidemia may be related to high rates of BSI in general in
Italian public hospitals, reasons for these high rates are not clear
and warrant further study. Determining factors associated with
these high rates may lead to identifying measures that can help to
prevent disease.
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